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Abstract
Background: Local IgE production may play a role in asthma pathogenesis. The aim of the study was to assess sputum total
IgE and cytokines in asthmatics according to sputum cellular phenotype.
Methods: We studied 122 subjects including 22 non atopic healthy subjects, 41 eosinophilic (sputum eosinophils $3%), 16
neutrophilic (sputum neutrophils .76%) and 43 pauci-granulocytic asthmatics (sputum eosinophils ,3% and sputum
neutrophils #76%) recruited from the asthma clinic at CHU Liege. Sputum supernatant total IgE (tIgE) was measured by
ImmunoCAP and sputum supernatant cytokines (IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, IFN-c and TNF-a) were measured with the
Luminex xMAP Technology by using commercially available Fluorokine MAP kits.
Results: After concentrating sputum samples, total IgE was detectable in the majority of subjects. Sputum IgE was raised in
asthmatics when compared to healthy subjects. Overall, asthmatics did not significantly differ from healthy subjects with
respect to cytokine levels. The eosinophilic asthma phenotype, however, was characterised by raised sputum tIgE, IL-5 and
IL-13 compared to healthy subjects (p,0.001, p,0.001 and p,0.05 respectively) and pauci-granulocytic asthma (p,0.01,
p,0.001 and p,0.05 respectively) and raised IL-5 compared to neutrophilic asthma (p,0.01). When patients were classified
according to sputum IgE levels, it appeared that IL-5, IL-6, IL-17 and TNF-a sputum supernatant levels were raised in the ‘‘IgE
high’’ asthmatics (IgE $0.1 kU/l) when compared to ‘‘IgE low’’ asthmatics (IgE,0.1 kU/l).
Conclusion: The eosinophilic asthma phenotype was associated with raised sputum IgE and a Th2 cytokine profile. Raised
sputum IgE was associated with a heterogeneous cytokine overproduction.
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Introduction
It is now recognised that asthma actually comprises several
inflammatory phenotypes and Simpson has proposed to break
down asthma according to the granulocyte fraction contained in
sputum cells [1]. Asthma is generally seen as an eosinophilic
disease [2]. However, several studies showed that a fraction of
asthmatic patients who exhibited the clinical symptoms of asthma
and airway hyperresponsiveness do not have raised sputum
eosinophils [3] and that this non-eosinophilic pattern of inflam-
mation occurs across the all spectrum of severity [4–6]. A fraction
of non-eosinophilic asthmatics actually exhibit raised airway
neutrophilic inflammation. Those patients with non-eosinophilic
asthma appear to be relatively resistant to corticosteroid therapy
and are likely to recognize different underlying molecular
mechanisms [7].
Local production of IgE might not be reflected by serum IgE or
atopic status. Very recent data have shown that tIgE and specific
IgE may be measurable in sputum from asthmatics irrespective of
their atopic status even if their ability to prime local mast cells is
still unclear [8]. However, it has also been demonstrated that local
IgE in nasal polyp samples is functional [9] and is associated with
comorbid asthma [10]. Monomeric IgE binding to its high affinity
receptor FceRI results in cell activation and survival independent
of the presence of any allergen [11;12]. This makes of local IgE an
important mediator in the mast cell activation pathway.
Recent studies demonstrated that total IgE in asthmatics is
related to specific IgE against Staphylococcus aureus enterotoxins,
which is found to be highly frequent in severe asthmatics
independent of the atopic status [13–15]. Interestingly, spec IgE
to Staphylococcus aureus enterotoxins is associated with lower
FEV1, and higher intake of oral glucocorticosteroids and
hospitalisation due to asthma exacerbations.
How local IgE production is related to the airway cellular
inflammatory profile remains poorly studied. It is assumed that
IgE production is tightly regulated by the balance between Th1
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and Th2 cytokines, interleukin-4 and 13 being involved in the
immunological switch towards IgE [16]. Il-5 is a cytokine
recognized to be critical in promoting eosinophilic inflammation
[17]. Beside classical Th2 profile there has been recent interest for
the IL-17 pathway in asthma and in particular in severe
neutrophilic asthma [18]. Whether IL-17 pathway and neutro-
philic asthma are related to disease severity and local IgE synthesis
has not been studied so far. Classically, IL-6 has been viewed as a
pro-inflammatory cytokine. Recent advances have documented a
series of IL-6 activities that are critical for resolving innate
immunity and promoting acquired immune responses [19]. TNF-
a is a potent pro-inflammatory cytokine that favours granulocytes
recruitment and which as been associated with asthma pathogen-
esis [20].
The purpose of our study was to assess tIgE (sputum
supernatant total IgE) , serum IgE and sputum cytokines in a
large sample of asthmatics classified according to their sputum
cellular phenotype. We also aimed to determine whether IgE and
cytokines were related to disease severity or atopy.
Materials and Methods
Study design and subjects characteristics
Patient demographic, functional and treatment characteristics
are given in table 1. In this study we enrolled 100 subjects
consecutively recruited from our asthma clinic at CHU Liege (41
eosinophilic, 16 neutrophilic and 43 pauci-granulocytic asthmat-
ics). All asthmatics were diagnosed on the basis of significant FEV1
reversibility ($12% from baseline) to b2-agonists or bronchial
hyperresponsiveness to methacholine (PC20 M,16 mg/ml). Ato-
py was defined as a positive skin prick test reaction (weal $3 mm
compared with control) to common aeroallergens including house
dust mites, cat and dog dander, grass, tree, pollen and moulds.
Different groups of asthmatics were compared to 22 non atopic
healthy subjects. The eosinophilic asthma phenotype was defined
by a sputum eosinophil count $3% while sputum was considered
to be neutrophilic when neutrophil count exceeded 76% (mean
+1.7 SD of neutrophil count derived from a population of 113
healthy subjects with a mean age of 37 years). Contrary to
eosinophils, the range of the upper limit of the 90% confidence
interval for neutrophils can considerably vary according to the
different labs (from 49% to 93%) [21]. Those who had less than
3% eosinophil count and less than 76% neutrophil count were
considered as pauci-granulocytic. Those with eosinophil count
Table 1. Demographic, functional, airway inflammatory and treatment characteristics according to sputum cellular profile.
Healthy subjects
(N=22)
Eosinophilic asthma
(N=41)
Neutrophilic asthma
(N=16)
Pauci-granulocytic asthma
(N=43)
Age (years) 42613 54611* 51617 38614 {{{
Sex (m/f) 14/8 26/15 5/11 20/23
Tobacco status (ns/es/cs) 15/3/4 18/16/7 10/4/2 24/9/10
Pack-year 16611 (N = 7) 19621 (N = 19) 42617 { (N = 6) 16614 { (N = 18)
BMI 2566 2764 2666 2665
Atopy 0 23 (56%) 7 (43%) 25 (58%)
FENO50 (ppb) 21 (6–48) 52 (9–222)* 20 (6–200) 16 (5–81) {{{
FEV1 (%) 103616 82626** 70625*** 90616 *
FVC (%) 108613 95622 83620*** 97613
FEV1/FVC (%) 8167 70613** 67615* 76610
Reversibility (%) – 16619 9612 10615
PC20M (mg/ml) . 16 mg/ml 0.81 (0–15) 0.46 (0.1–14) 0.56 (0.2–14)
ACQ ND 1.6 (0–5.1) 2.1 (0–4.7) 1.7 (0–4.4)
Blood eosinophils (%) 1.7 (0.7–6) 5 (2–24)*** 2 (0.2–5){{ 2 (0.3–9) {{{
Blood neutrophils (%) 53 (47–69) 52 (40–65) 63 (50–79){{ 55 (42–72)
Sputum eosinophils (%) 0 (0–11) 14 (3–89)*** 0.2 (0–2.7){{{ 0.5 (0–2.6) {{{
Sputum neutrophils (%) 35 (0–88) 37 (3–68) 91 (80–100)*** {{{ 47 (0–76) {{{
ICS 0 26 (63%) 11 (69%) 25 (58%)
ICS (eq becl/day) 0 2000 (400–2000) 2000 (500–4800) 1000 (400–3000)
LABA 0 21 (51%) 10 (62%) 18 (42%)
LTRA 0 8 (20%) 1 (6%) 9 (21%)
Theophylline 0 2 (4.9%) 3 (19%) 2 (4.6%)
Hospi/patient/year 0 0.2460.43 0.2560.44 0.1960.39
Exacerbation/patient/year 0 1.0961.93 0.8161.64 0.962.07
Oral CS$50% time 0 1 (2.4%) 2 (12.5%) 2 (4.6%)
Age, BMI, lung function, hospi/patient/year and exacerbation/patient/year are expressed as mean 6 SD, PC20M as geometric mean and other parameters as median
(range), becl = beclomethasone, * p,0.05, ** p,0.01, *** p,0.001 vs healthy subjects; { p,0.05, {{ p,0.01, {{{ p,0.001 vs eosinophilic; { p,0.05, {{ p,0.01,
{{{ p,0.001 vs neutrophilic. ND= not defined.
doi:10.1371/journal.pone.0058388.t001
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.3% and neutrophil count .76% were considered as mixed
granulocytic but discarded from further analysis because only 3
patients satisfied these criteria. A subgroup of our asthmatic
population was considered as refractory asthmatics (N= 35). They
were defined according to the ATS criteria and had been followed
for at least 6 months in our department and received education
about their disease before entering this study.
The protocol had been approved by the local Ethics Committee
(Hospital-Faculty ethics committee of Liege University) and every
subject gave his written informed consent.
Peripheral blood sampling, serum IgE and cell count
measurement
Peripheral blood samples were collected in serum tubes with gel
(Venosafe, TERUMOH, Belgium). Tubes were centrifuged at
800 g for 10 min at 4uC and sera were conserved into aliquots at
280uC until assay. The total and differential blood cell counts
were obtained with an Advia 210 automatic counter (USA).
Counting and cell typing were based on flow cytometry with
bidimensionnal volume distribution, peroxydase concentration
and lobularity of leukocytes as parameters. Serum total IgE, serum
specific IgE against staphylococcus aureus and serum specific IgE
against the most common aeroallergens were measured with the
ImmunoCAP system with a detection limit of 2 kU/l, 0.1kU/l and
0.35 kU/l respectively (Phadia AB, Uppsala; Sweden).
Sputum induction and processing
After premedication with 400 mg inhaled salbutamol adminis-
tered by MDI (+ Spacer), sputum was induced by inhalation of
hypertonic saline (NaCl 5%) when FEV1 post salbutamol was
$65% predicted and isotonic saline (NaCl 0.9%) when FEV1 was
,65% predicted. Saline was combined with additional salbutamol
delivered by an ultrasonic nebuliser (Ultra-Neb 2000, Devilbiss)
with an output set at 0.9ml/min as previously described [22]. Each
subject inhaled the aerosol for three consecutive periods of 5 min
and for a total time of 15 min. For safety reasons, FEV1 was
monitored every 5 min and the induction stopped when FEV1 fell
by more than 20% from post-bronchodilatation values.
The whole sputum was collected in a plastic container, weighted
and homogenized by adding three volumes of phosphate-buffered
saline (PBS), vortexed for 30 sec and centrifuged at 800 g for
10 min at 4uC. Supernatant was separated from cell pellet. We
added DTT (dithiotreitol) to the cells which were agitated for
20 min. Cells were washed once more with PBS and resuspended
in 1ml. Squamous cells, total cell counts and cell viability checked
by trypan blue exclusion were performed with a manual
haemocytometer. When squamous cells were .80% the sample
was considered inappropriate. 90% of the samples used for our
study had squamous cell count ranging from 0 to 50% [23]. The
differential cell count was performed on cytospins stained with
Diff-Quick after counting 400 cells.
Sputum IgE and cytokines measurement
All induced sputum samples were concentrated by use of
centrifugal evaporator. 1 ml of induced sputum was entirely
airdried in a SpeedVac SC 100 centrifuge (Savant, Thermo
Scientific). Afterwards the pellet was resuspended in 100 ml
distilled water and mixed. Total sputum IgE was measured with
ImmunoCAP system with a detection limit of 0.1 kU/l (Phadia
AB, Uppsala; Sweden).
All samples were assayed for IL-4, IL-6, IL-10, IL-5, IL-17, IL-
13, IFN-c and TNF-a with the Luminex xMAP Technology by
using commercially available Fluorokine MAP Kits (R&D Systems
Europe Ltd, Abingdon, United Kingdom) following to the
manufacturers guidelines and measured on a Bio-Plex 200
Platform (Bio-Rad Laboratories S.A.-N.V, Nazareth Eke, Bel-
gium). The detection limits were 3pg/ml for IL-17, 1.5pg/ml for
IL-5, 4 pg/ml for IFN-c, 4 pg/ml for TNF-a, 2 pg/ml for IL-6, 1
pg/ml for IL-4, 11 pg/ml for IL-13 and 0.5 pg/ml for IL-10.
Spiking experiments of cytokines in sputum supernatants showed
that recovery ranged from 71% for IL-4 to 133% for interferon-
gamma.
Statistical analysis
Results were expressed as median (range) unless otherwise
stated. Comparisons between the four groups were performed by
Kruskall-Wallis Test (non parametric ANOVA) followed, in case
of significance, by Dunn’s multiple comparisons Test. Correlations
were performed by calculating the Spearman coefficient. A P value
,0.05 was considered as statistically significant.
Results
Patient characteristics
Demographic, lung function, airway inflammation and treat-
ment characteristics according to sputum cellular profile are given
in table 1. Exhaled nitric oxide (FeNO50) was higher in
eosinophilic asthmatics compared to healthy subjects (p,0.05)
and pauci-granulocytic asthmatics (p,0.001). FEV1 values were
clearly altered in eosinophilic (p,0.01), neutrophilic (p,0.05) and
pauci-granulocytic (p,0.001) when compared to healthy subjects.
FVC was diminished in the neutrophilic group when compared to
healthy subjects (p,0.001) and the ratio FEV1/FVC was also
significantly decreased in both eosinophilic and neutrophilic
Figure 1. Sputum total IgE in asthmatics according to sputum
cellular profile.
doi:10.1371/journal.pone.0058388.g001
Figure 2. Correlation between sputum total IgE and serum
total IgE in asthmatics.
doi:10.1371/journal.pone.0058388.g002
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asthmatics (p,0.01 and p,0.05 respectively). ACQ score was
quite similar between the asthmatic groups.
The majority of our asthmatics were taking inhaled corticoste-
roids combined for most of them with long-acting b-2 agonists.
Some of them were also receiving theophylline or leucotriene
receptor antagonists (Table 1).
Sputum IgE and cytokine levels in the all group of
asthmatics
Total IgE was detectable in the sputum supernatant from the
majority of subjects (70%). Overall, asthmatics had greater sputum
IgE levels when compared to healthy subjects {0.3 (0–31) vs 0.1 (0–
5.4)} (p,0.001). By contrast, there was no significant difference
between asthmatics and healthy subjects regarding cytokine levels
even if there was a trend for higher IL-5 levels in asthmatics {0 (0–
125) vs 0 (0–27)} (p = 0.07).
Sputum and serum IgE and sputum cytokine levels
according to sputum cellular phenotype
When patients were classified according to their sputum
cellularity, there were 41 eosinophilic ($3%), 16 neutrophilic
(.76%), 43 pauci-granulocytic and 3 mixed granulocytic. Sputum
tIgE were increased in eosinophilic asthmatics when compared to
healthy subjects (p,0.001) and pauci-granulocytic asthmatics
(p,0.01) (Fig. 1) (Table 2). Overall sputum IgE was correlated
with serum IgE (Fig 2). Serum total IgE (tIgE) were lower in
neutrophilic than in eosinophilic asthmatics and healthy subjects
(p,0.05 for both). Specific IgE towards classical aeroallergens or
Table 2. Total sputum and serum IgE, serum specific IgE and sputum cytokine levels according to sputum cellular phenotype.
Healthy subjects
(N=22) Eosinophilic (N=41) Neutrophilic(N=16) Pauci-granulocytic(N=43)
Sputum IgE (kU/l) 0.1 (0–5.4) 0.6 (0.02–31)*** 0.2 (0.02–8) 0.2 (0.02–6) {{
Serum IgE (kU/l) 72 (5–195) 222 (9–9235)*** 44 (7–1670){* 125 (7–2177) *
Serum spec IgE against Staph
aureus enterotoxins (kU/l)
ND 0.28 (0–23) 0.05 (0–44) 0.35 (0–2)
Serum spec IgE against Staph
aureus enterotoxins (positive-%)
ND 14 (82%) (N = 17) 4 (50%) (N = 8) 11 (79%) (N = 14)
House dust mite (positive-%) - 19 (46%) 4 (25%) 21 (49%)
Cat (positive-%) - 10 (24%) 5 (31%) 16 (37%)
Dog (positive-%) - 6 (15%) 5 (31%) 11 (26%)
Moulds (positive-%) - 5 (12%) 3 (19%) 6 (14%)
Grass pollen (positive-%) - 11 (27%) 5 (31%) 16 (37%)
Birch pollen (positive-%) - 12 (29%) 2 (13%) 8 (19%)
IL-17 (pg/ml) 0 (0–11) 0 (0–51) 0 (0–99) 0 (0–17)
IL-5 (pg/ml) 0 (0–27) 6 (0–125)*** 0 (0–15) {{ 0 (0–40) {{{
IFN-c (pg/ml) 0 (0–0) 0 (0–13) 0 (0–0) 0 (0–192)
TNF-a (pg/ml) 8 (0–146) 5 (0–54) 7 (0–830) 4 (0–194)
IL-6 (pg/ml) 70 (12–158) 59 (0–487) 35 (2–1183) 83 (5–1002)
IL-4 (pg/ml) 0 (0–0) 0 (0–19) 0 (0–0) 0 (0–15)
IL-13 (pg/ml) 0 (0–18) 11 (0–189)* 0 (0–26) 0 (0–75) {
IL-10 (pg/ml) ND 0 (0–3) 0 (0–0) 0 (0–21)
*p,0.05, **p,0.01, *** p,0.001 vs healthy subjects, { p,0.05, {{ p,0.01, {{{ p,0.001 vs eosinophilic asthmatics, ND= not done, spec = specific. Results are
expressed as median (range) except as otherwise stated.
doi:10.1371/journal.pone.0058388.t002
Figure 3. IL-5 and IL-13 levels in asthmatics according sputum cellular profile.
doi:10.1371/journal.pone.0058388.g003
Sputum IgE and Cytokines in Asthma
PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e58388
SA enterotoxins were not associated with any particular cellular
phenotype (Table 2).
As far as cytokines are concerned, IL-5 was increased in
eosinophilic asthmatics when compared to healthy subjects
(p,0.001), neutrophilic (p,0.01) and pauci-granulocytic
(p,0.001). Eosinophilic asthmatics were also characterized by
greater IL-13 levels when compared with healthy subjects and
pauci-granulocytic patients (p,0.05 for both) (Fig 3). No
difference was found regarding other tested cytokines (Table 2).
Patient’s characteristics and cytokine levels in ‘‘IgE high’’
vs ‘‘IgE low’’ asthmatics
When asthmatic patients were classified according to their
sputum IgE profile, there was no statistical difference regarding
age, FeNO, spirometric values or ACQ. However, asthmatics with
the ‘‘IgE high’’ phenotype were more atopic (p,0.01) than ‘‘IgE
low’’ asthmatics. They were also characterized by raised sputum
(p,0.001) and blood (p,0.01) eosinophils and raised blood
neutrophils (p,0.05) (Table 3).
Regarding the cytokine profile, ‘‘IgE high’’ distinguished from
‘‘IgE low’’ asthmatics by raised IL-5 (p,0.0001), IL-6 (p,0.01),
IL-17 (p,0.05) and TNF-a (p,0.01) from their sputum superna-
tant (Table 4) (Fig 4).
As for serum specific IgE in these two groups of asthmatics, we
found that the ‘‘IgE high’’ phenotype was characterized by raised
serum specific IgE directed against staphylococcus aureus
(p,0.01). The ‘‘IgE high’’ group had also more often detectable
IgE towards cat (p,0.05) and grass pollen (p,0.01) (Table 4).
Sputum and serum IgE and sputum cytokine levels
according to disease severity, atopy and smoking status
Mild-to-moderate treated and untreated asthmatics as well as
refractory asthmatics had higher tIgE than healthy subjects
(p,0.05 and p,0.01 for refractory) but groups of asthmatics did
not differ from each other. Similar to what was seen in sputum,
total serum IgE were not different between the asthmatic groups.
The demographic and functional characteristics of refractory
asthmatics are given in Table 5.
Atopic asthmatics distinguished from healthy subjects and non-
atopic asthmatics by raised sputum IgE levels {0.36 Ku/l (0–31.2)
vs 0.1 Ku/L (0–5.4) (p,0.001) and vs 0.16Ku/L (0–12.1)
(p,0.05) respectively}. However a few non atopic asthmatics
exhibited high sputum IgE levels. No difference was observed
regarding sputum cytokine levels between atopic asthmatics and
non atopic asthmatics and healthy subjects (data not shown).
However, when we split ‘‘IgE high’’ asthmatics into atopic and
non-atopic, we found that non-atopic were characterized by raised
IL-5 {6 (0–125) vs 2 (0–59)(p,0.05)} and TNF-a {14 (0–829) vs 5
(0–274) (p,0.05) } and a trend for raised IL-6 (p= 0.08) when
compared to IgE high atopic asthmatics. Excluding the current
smokers from the asthmatic group does not alter the main findings
regarding IgE and cytokines (data not shown).
Table 3. Demographic, functional, airway inflammatory and treatment characteristics in ‘‘IgE high’’ vs ‘‘IgE low’’ asthmatics.
‘‘IgE high’’ asthmatics (N=74) ‘‘IgE low’’ asthmatics (N=26)
Age (years) 47616 48617
Sex (m/f) 40/34 9/17
Tobacco status (ns/es/cs) 37/22/15 16/7/3
BMI 2665 2665
Atopy 51 (69%) ** 7 (27%)
FENO50 (ppb) 28 (4–222) 18 (8–104)
FEV1 (%) 82624 83625
FVC (%) 93619 91621
FEV1/FVC (%) 72613 71612
Reversibility (%) 12617 15616
PC20M (mg/ml) 0.65 (0.4–14) 0.4 (0.1–14)
ACQ 1.71 (0–5.14) 1.71 (0–4.2)
Blood eosinophils (%) 4 (0.3–24) ** 1.8 (0.2–7)
Blood neutrophils (%) 53 (40–72) * 63 (45–79)
Sputum eosinophils (%) 3 (0–89) *** 0.1 (0–24)
Sputum neutrophils (%) 49 (3–100) 54 (0–97)
ICS 51 (69%) 14 (52%)
ICS (eq bud/day) 1600 (400–4800) 2000 (400–4800)
LABA 41 (55%) 10 (38%)
LTRA 13 (18%) 5 (19%)
Theophylline 5 (7%) 4 (15%)
Hospi/patient/year 0.2260.42 0.1560.37
Exacerbation/patient/year 1.0262.07* 0.4660.98
Oral CS$50% time 3 (4%) 1 (3.8%)
*p,0.05, ** p,0.01, ***p,0.001 vs IgE low asthmatics. Age, BMI, lung function, hospi/patient/year and exacerbation/patient/year are expressed as mean 6 SD, PC20M
as geometric mean and other parameters as median (range).
doi:10.1371/journal.pone.0058388.t003
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Discussion
Our study shows that eosinophilic asthmatics have higher total
IgE concentrations in the sputum as compared to pauci-
granulocytic asthmatics and healthy subjects. Likewise eosinophilic
asthmatics exhibited a peculiar cytokine profile featuring raised
Th2 IL-5 and IL-13 levels. We provide evidence for an airway
Table 4. Total sputum and serum IgE and sputum cytokine levels in ‘‘IgE high’’ vs ‘‘IgE low’’ asthmatics.
‘‘IgE high’’ asthmatics (N=74) ‘‘IgE low’’ asthmatics (N=26)
Sputum IgE (kU/l) 0.5 (0.1–31) **** 0 (0–0)
Serum IgE (kU/l) 290 (9–9235) **** 33 (7–248)
Serum spec IgE against staph aureus enterotoxins (kU/l) 0.5 (0–44) ** 0.1 (0–0.15)
Serum spec IgE against staph aureus enterotoxins (positive-%) 26 (87%) (N = 30) 5 (62%) (N = 8)
House dust mite (positive-%) 37 (50%) 8 (31%)
Cat (positive-%) 30 (40%) * 3 (11%)
Dog (positive-%) 21 (28%) 2 (7%)
Moulds (positive-%) 13 (18%) 1 (4%)
Grass pollen (positive-%) 29 (39%) * 3 (11%)
Birch pollen (positive-%) 19 (26%) 2 (7%)
IL-17 (pg/ml) 3 (0–99) * 0 (0–12)
IL-5 (pg/ml) 3 (0–125) **** 0 (0–3)
IFN-c (pg/ml) 0 (0–193) 0 (0–0)
TNF-a (pg/ml) 6 (0–830) ** 0 (0–11)
IL-6 (pg/ml) 62 (0–1051) ** 27 (2–1182)
IL-4 (pg/ml) 0 (0–19) 0 (0–3)
IL-13 (pg/ml) 0 (0–188) 0 (0–37)
IL-10 (pg/ml) 0 (0–21) 0 (0–2)
*p,0.05, ** p,0.01, **** p,0.0001 vs IgE low asthmatics. ND= not done, spec = specific. Results are expressed as median (range) except as otherwise stated.
doi:10.1371/journal.pone.0058388.t004
Figure 4. Cytokine levels in ‘‘IgE high’’ and ‘‘IgE low’’ asthmatics.
doi:10.1371/journal.pone.0058388.g004
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‘‘IgE high’’ phenotype that was associated with raised IL-5, IL-6,
IL-17 and TNF-a.
There are limited data in the literature on soluble IgE in the
airways of asthmatics. Our data are in keeping with the recent
finding of Mouthuy et al and extend our knowledge in the field by
showing that sputum IgE levels are not related to disease severity
but clearly increased in those exhibiting airway eosinophilic
inflammation. The role of IgE has been traditionally assigned to
allergic reaction towards an aeroallergen in sensitized patients. In
the nineties, Humbert et al have drawn attention to the potential
role of IgE in non-atopic asthma by showing increased expression
of the receptor FceRI in the bronchial mucosa in asthmatics
irrespective of the atopic status [24]. Mast cells are major effector
cells in IgE dependent immediate hypersensitivity reactions and in
IgE associated immune responses against certain parasites [25;26].
The liaison of an allergen to IgE bound at the mast cell surface is a
powerful event leading to mast cell degranulation [11]. However,
it is now admitted that the binding of IgE itself to its high affinity
receptor at cell surface is an event sufficient to trigger cell
activation [12]. More than 10 years ago, Nahm et al validated the
induced sputum model as a non-invasive method for studying
allergen-specific IgE antibodies in airway secretion from asthmatic
patients [27]. They found that house dust mite specific IgE were
detected in induced sputum supernatant from 7 of 10 house dust
mite sensitive asthmatics based on skin prick tests. Moreover, a
very recent study has shown that IgE production occurs both in
atopic and in intrinsic asthma and that part of this IgE recognizes
Der p antigens [8]. In contrast to what Mouthuy et al reported, we
found that sputum IgE levels were higher in atopic than in non
atopic asthmatics and that, overall, non atopic asthmatics did not
distinguish from non atopic healthy subjects [8]. This, however,
does not preclude the possibility that non atopic asthmatics still
have greater levels of sputum IgE directed towards common
aeroallergens as shown by Mouthuy et al with respect to IgE
against house dust mites. Moreover we found a convincing
relationship between sputum and serum IgE in our group of
asthmatics suggesting that part of the sputum IgE may be related
to plasma exsudation. Alternatively this might reflect a global
predisposition to produce IgE in several compartments of the
body.
Here, in a large group of asthmatics, we have assessed whether
sputum IgE and cytokines may be related to the sputum cellular
profile. Eosinophilic asthmatics clearly distinguished from healthy
subjects and pauci-granulocytic asthmatics by raised sputum IgE.
Our study reveals, but not explores, the mechanisms underlying
this strong relationship. It is well known from bronchial allergenic
challenge experiments that mast cell activation by an allergen
exposure is a powerful event to stimulate eosinophil tissular
recruitment [28]. We currently lack predictive factors of a good
response to anti-IgE [29]. Our study supports suggestions that
treatment with anti-IgE may be particularly efficient in eosino-
philic asthmatics. By contrast to what is seen in eosinophilic
asthmatics, neutrophilic asthmatics were characterised by lower
IgE both at the airway and at the systemic level. This is in
agreement with the view that neutrophilic asthma is less
dependent on IgE mediated reaction but rather related to
pollutant exposure or infections [30]. Here, neutrophilic asthma
was defined by at least 76% neutrophils in the sputum. This was
based on our own lab references values. In the literature, the
definition can vary considerably according to the authors.
However, performing the analysis with a threshold set at 61%
for the sputum neutrophil count did not change the main message
of this paper (data not shown). The reasons why there is such a
variation in sputum neutrophils in healthy subjects remain
controversial but may be linked to age of the population as well
as its current exposure to aero-pollutants.
Regarding the cytokine profile, eosinophilic asthmatics display
raised IL-5 and IL-13 sputum supernatant levels when compared
with healthy subjects, neutrophilic and pauci-granulocytic asth-
matics. IL-5 is a Th2 cytokine known to be able to promote
eosinophil differentiation and release from the bone marrow into
the blood stream. Moreover, this cytokine has also a chemotactic
effect on eosinophils and enhances secretion, cytotoxicity and
survival [31]. Therefore, it is not surprising that IL-5 appears to be
strikingly linked to the eosinophilic pathway [32]. IL-13 is another
Th2 cytokine thought to be a central mediator of inflammation in
asthma. It has pleiotropic effects that mimics key features of
asthma like increased smooth muscle contractility [33] or mucus
secretion [34] and shares the same heterodimer receptor as IL-4
by binding to the a chain [35]. Berry M et al have investigated
whether IL-13 expression and production was increased in
asthma. They found greater IL-13 protein expression in bronchial
biopsies by immunohistochemistry with eosinophils being the
major source of IL-13 within the bronchial mucosa. Furthermore
levels of IL-13 measured by ELISA were also raised in asthmatics
[36]. Those findings are in keeping with our demonstration that
raised sputum IL-13 levels were only found in eosinophilic
asthmatics. However the fact that IL-13, like IL-5, is not increased
in non eosinophilic asthma indicates that these Th2 cytokines are
essentially related to a peculiar inflammatory profile rather than to
asthma itself. This is in keeping with the study of Erin et al who
showed that IL-5 and IL-13 were elevated in patients with severe
eosinophilic asthma although in contrast to what found Erin et al
we did not find an increase of IL-4 in our study [37]. Nevertheless
eosinophilic bronchitis, while showing high IL-5 production, fails
to discriminate from healthy subjects by increased IL-13
production [36;38].
It is common belief that a Th2 microenvironment is crucial in
underlying atopy, this inherited predisposition to mount an IgE
response towards common aeroallergens. Our data show, howev-
er, that Th2 profile is rather associated with eosinophilic
inflammation than with atopy. Moreover, our data show IgE high
non-atopic asthmatics were characterized by a cytokine profile
featuring raised IL-5, IL-6 and TNF-a. On the other hand, it is
well recognised that eosinophilic inflammation may develop in
asthma irrespective of the atopic status [39]. However, it is
noteworthy to highlight that the non-eosinophilic phenotype
including pauci-granulocytic and neutrophilic asthma represents
a major part of asthmatic population which is in agreement with a
recent study by Mc Grawth et al. Our data clearly indicate that
non-eosinophilic asthma is characterized by different molecular
mechanisms than eosinophilic asthma. This is likely to have
important consequences in terms of treatment efficacy [3;40].
Here we propose a new biochemical asthma phenotype based
on the detection of IgE in the sputum. When patients were
classified according to their IgE phenotype, we found raised IL-5,
IL-6, IL-17 and TNF-a in the ‘‘IgE high’’ asthmatic subgroup.
The role of IL-5 in asthma and its relationship with eosinophils has
already been discussed (see above). Besides, IL-5 together with IL-
6 can promote IgE synthesis and increases IL-4-dependent IgE
synthesis [41]. It may appear somewhat surprising that IL-17 was
associated with the high sputum IgE and not with the neutrophilic
phenotype as IL-17 has been shown to promote neutrophil
recruitment and activation [42] and as some patients with hyper-
IgE syndrome were shown to be deficient in IL-17 secreting T cells
as a result of STAT3 mutation [43]. Our finding also contrast to
what Bullens et al reported using sputum mRNA but mRNA and
proteins levels are not necessarily tightly related [44]. The reason
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why IL-17 was not associated with neutrophilic inflammation in
our study is not clear but our data point out the fact that Th2 and
Th17 pathways may be operating together in those asthmatics
exhibiting high IgE levels in their airways. The association
between the high IgE phenotype and high TNF-a and IL-6
sputum levels is in keeping with the fact that mast cells are a potent
source of TNF-a and IL-6 that may be activated by monomeric
IgE [12]. Treatment with anti-TNF-a has generally proved rather
disappointing in asthma [45;46]although some reports had shown
convincing and promising responses [47;48]. Our study shows that
those patients with high IgE in the sputum might perhaps be
suitable targets for anti TNF-a treatment. In our hands, cytokines
like IL-4, IFN-c and IL-10 were undetectable in the majority of
patients. Sputum processing with a mucolytic agent may influence
the level of cytokines measured in the supernatant [49]. In our
study we cannot, however, incriminate the use of DTT as the
supernatant was only diluted with PBS, the mucolytic agent being
reserved to the cellular part for improving the quality of cytospins.
Furthermore, recovery from spiking experiments was excellent
indicating that the poor detection of some of them cannot be
accounted for by cytokine trapping in sputum supernatant
heterogeneous milieu.
Conclusion
Our study shows that asthmatics have raised sputum IgE levels
associated with the eosinophilic phenotype and that the airway
‘‘IgE high’’ is characterized by a global cytokine overproduction
not limited to a Th2 profile. Overall, our study point to the cellular
and molecular heterogeneity in asthma, which calls upon targeted
treatments. If new biologicals for asthma treatment have to fulfil
our expectations, they certainly must be tested in selected
asthmatic population.
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